Table 3.

Cox Models for Months to Death

	Model 0	Model 1	Model 2	Model 3*
N	6523	6791	6523	2758
n (%) Censored	1447 (22.2%)	1496 (22.0%)	1447 (22.2%)	705 (25.6%)
Variable	HR (95% CI)**	HR (95% CI)	HR (95% CI)	HR (95% CI)
Treatment Decision (vs. Treatment/No Hospice [Group 3]):
No Treatment/No Hospice [Group 1]		1.08 (1.002–1.17)	1.61 (1.48–1.75)	1.40 (1.23–1.58)
Treatment/Hospice [Group 4]		2.98 (2.68–3.31)	2.09 (1.88–2.33)	1.99 (1.69–2.35)
No Treatment/Hospice [Group 2]		3.40 (3.13–3.69)	2.90 (2.66–3.18)	2.84 (2.48–3.25)
Total ADL score:
First Assessment				1.04 (1.03–1.05)
Improvement				0.93 (0.92–0.95)
Male (vs. Female)	1.16 (1.10–1.23)		1.17 (1.11–1.24)	1.20 (1.10–1.32)
Age at Index Admission (10 years)	1.19 (1.14–1.23)		1.06 (1.02–1.11)
Months between Diagnosis and Index Admission	0.93 (0.90–0.96)		0.93 (0.91–0.96)	0.94 (0.90–0.98)
SES
Median Income ($10,000)	0.98 (0.97–0.99)		0.98 (0.97–0.99)
Charlson Comorbidity Index Categories	1.07 (1.05–1.10)		1.05 (1.03–1.08)
Cancer Type (vs. Colorectal)
Lung	1.87 (1.72–2.03)		1.88 (1.73–2.04)	2.06 (1.81–2.35)
Pancreas	2.29 (2.05–2.57)		2.20 (1.96–2.46)	2.36 (1.97–2.84)
Bladder	1.89 (1.64–2.18)		1.80 (1.56–2.07)	1.86 (1.51–2.30)
Cancer Stage (vs. Stage IV)
Stage II	0.34 (0.31–0.37)		0.35 (0.32–0.38)	0.38 (0.33–0.43)
Stage III	0.52 (0.48–0.56)		0.56 (0.52–0.60)	0.58 (0.52–0.66)
Grade (vs. 9)
1	0.43 (0.36–0.52)		0.48 (0.40–0.58)	0.48 (0.36–0.64)
2	0.61 (0.56–0.67)		0.66 (0.60–0.73)	0.70 (0.61–0.82)
3	0.87 (0.80–0.94)		0.93 (0.86–1.005)	0.97 (0.86–1.10)
4	0.90 (0.78–1.03)		0.98 (0.85–1.12)	1.16 (0.94–1.43)
Index LOS (10 days)	1.07 (1.03–1.10)		1.09 (1.05–1.13)

^*Many cases were not used in the model since improvement in total ADL score was available for only 2758 patients.

^**Hazard Ratio (95% Confidence Interval)